Latest Biotech News

Guardant Health and Zephyr AI announced a strategic partnership to combine Guardant’s multimodal molecular datasets with Zephyr’s AI analytics to accelerate discovery of genomic biomarkers for...

An MIT research team released BoltzGen, an open‑source generative model that moves from structural prediction toward generalizable therapeutic design across modalities including small molecules,...

MapLight Therapeutics filed for and priced a $250 million IPO to develop a competitor to Bristol Myers Squibb’s schizophrenia drug Cobenfy. The proceeds will finance clinical development of the...

Revvity reported third‑quarter results with 2% overall revenue growth to $698.9 million and a 3% rise in diagnostics revenue driven by newborn screening and immunodiagnostics. The company cited...

Flagship Pioneering-backed Expedition Medicines launched with an AI‑driven platform that analyzes proteome chemistry to design small molecules for targets considered undruggable. The company...

Novartis agreed to acquire Avidity Biosciences for roughly $12 billion, adding three late-stage RNA-based programs aimed at muscular dystrophies and related neuromuscular diseases. The Swiss...

Hemab Therapeutics closed a $157 million financing to advance a pipeline targeting underserved bleeding disorders, including two clinical-stage candidates. The round was led by Sofinnova Partners...

Novo Nordisk returned to the table and completed a roughly $4.7 billion acquisition of MASH drug developer Akero Therapeutics after earlier walking away from talks. The transaction consolidates...

Flagship Pioneering launched Expedition Medicines, an AI-driven startup that claims to learn chemistry rules to bind historically undruggable proteins. The company announced an R&D alliance with...

GSK struck a $357 million agreement with French biotech Syndivia to access a preclinical antibody-drug conjugate (ADC) program for prostate cancer. The deal covers preclinical work and potential...

Town Hall Ventures closed a $440 million fund to invest in startups using AI to expand healthcare access and outcomes for underserved populations. The firm targets companies that combine clinical...

Two studies highlight advances in infectious-disease surveillance: one used metagenomic sequencing to resolve strain-level pneumonia pathogens, and another linked rotavirus RNA trends in...

New computational tools advanced by two research teams promise to improve diagnostic classification and single-cell analysis workflows. A multi-institution validation showed AI models can classify...

Preclinical studies identified actionable routes to reverse resistance to platinum chemotherapy: targeting FBXL5 sensitized iron-rich colorectal tumors to oxaliplatin via ferroptosis mechanisms,...

Two laboratory advances aim to improve preclinical translation: a 3D-printed scaffold model refined glioblastoma drug screening to better mimic tumor microenvironments, and a Cell paper showed...

Novartis moved to acquire Avidity Biosciences in a roughly $12 billion deal, adding a trio of late-stage RNA-based programs targeting Duchenne muscular dystrophy, myotonic dystrophy type 1 and...

GSK struck a pact worth up to $357 million with French biotech Syndivia for a preclinical prostate cancer antibody-drug conjugate (ADC). The agreement, disclosed after a European cancer conference...

Novo Nordisk walked away from earlier acquisition talks for Akero Therapeutics before returning to complete a $4.7 billion purchase of MASH drug developer Akero, according to reporting on the deal...

Flagship Pioneering launched Expedition Medicines, an AI-driven startup that claims to learn chemical rules to bind small molecules to historically 'undruggable' protein targets. The company...

Town Hall Ventures closed a $440 million fund to back startups deploying AI to improve healthcare access and outcomes for underserved populations. The fund, the firm’s fourth, signals growing...